Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies targeting gut-based receptors, specifically TAS2Rs, to treat metabolic diseases like hyperphagia and obesity. Its lead candidate, ARD-101, aims to regulate hunger via gut-brain signaling, with potential applications for rare disorders such as Prader-Willi Syndrome and hypothalamic obesity. The company focuses on innovative, gut-restricted compounds to improve efficacy and safety in metabolic health management.
This description was generated via AI from an annual report. Updated about 1 year ago.